Trial
NCT03771664
A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and Insomnia
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Biogen
Collaborators
—
Condition
Major Depressive Disorder
Intervention
SAGE-217
Why stopped
internal company decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-11-29